GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

The company’s consolidated profit excluding minority interest dropped to EGP 105.826 million in January-September from EGP 46.728 million a year earlier ...

GSK celebrates 100 years in India with former MDs, highlighting resilience and reinvention in the pharmaceutical industry.

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK plc announced the results of a GSK-sponsored multinational survey designed to raise awareness of challenges that people with gynaecologic cancers may experience. The survey, which was conducted by ...